Esketamine nasal spray presents a promising new frontier in the battle against treatment-resistant depression. While further research is warranted, the current findings offer hope to those seeking effective and rapid relief from the debilitating effects of depression. The K-hole phenomenon illuminates the precarious balance between the quest for altered states of consciousness and the stark reality of potential harm. Despite the risks, the allure of the K-hole continues to captivate some, showcasing the complex and sometimes dangerous relationship individuals share with substances like ketamine.

Enthea, a provider of psychedelic healthcare insurance plans, declared that it will expand its services into 40 markets across the US in 2023 with the goal of making workplace benefits for psychedelic-assisted therapies reasonable, equitable, and available.

Awakn Life Sciences Corp. , a psychedelic biotechnology company focused on researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder, has announced on June 2nd that they have initiated a larger behavioral addiction study investigating ketamine as a treatment for Gambling Disorder.

Today the hot news is that Ecstasy and psilocybin are shaking up psychiatry with psychedelic Therapy Schools Popping Up everywhere like little Magic Mushrooms! In addition to recently announced Hawaii, New Psychedelic Bills are being filed in Florida, Connecticut, Vermont and New Jersey, as the freedom of consciousness and natural medicine movement sweeps the globe.

Silo Wellness has recently gone public on the Canadian Securities Exchange. After launching a psilocybin nasal spray for Micro-Dosing, and psychedelic retreat centers in Jamaica and Oregon, Silo is currently only trading at 0.24 Cents per share!